Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that CFO and co-CEO James Martin will present at the Virtual Investor Summit Conference on March 29, 2023, at 10:30 a.m. Eastern time. The presentation will highlight significant advancements and upcoming milestones in their antiviral programs targeting influenza A, COVID-19, and norovirus. The company employs innovative structure-based technologies to develop novel antiviral therapeutics aimed at viral replication processes.

For more details, interested parties can register for the presentation online.

Positive

• Cocrystal is advancing antiviral programs targeting influenza A, COVID-19, and norovirus.
• The company employs unique structure-based technologies to develop novel antiviral therapeutics.

Negative

• None.

BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit Conference being held on Wednesday, March 29, 2023 at 10:30 a.m. Eastern time.

“This is a highly eventful time a Cocrystal with significant advancements and upcoming milestones with our antiviral influenza A, COVID-19 and norovirus programs,” said Mr. Martin. “We look forward to sharing our progress with the many investors tuning into this event.”

Registration for the live and archived virtual presentation is available here and on the IR Calendar of the Cocrystal website.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

# # #

FAQ

When will Cocrystal Pharma present at the Virtual Investor Summit Conference?

Cocrystal Pharma will present on March 29, 2023, at 10:30 a.m. Eastern time.

What will Cocrystal Pharma discuss at the upcoming investor conference?

The presentation will cover significant advancements and milestones in their antiviral programs.

What is Cocrystal Pharma's focus in antiviral drug development?

Cocrystal focuses on developing novel antiviral therapeutics targeting influenza A, COVID-19, and norovirus.

Who is presenting for Cocrystal Pharma at the conference?

James Martin, CFO and co-CEO, will present at the conference.